This study provided the first evidence that PAR-1 levels rise in COVID-19-affected T2DM patients, and it identified a positive correlation between serum BMI, PAR-1 levels, CRP, HbA1c, D-dimer, homocysteine, NT-proBNP, and other inflammatory mediators. Here, CRP is linked to COVID-19.